concluded that selective inactivation of SOCS3, by antagonists or otherwise, can attenuate insulin resistance, and that SOCS3 inhibitors could be an attractive therapy for treating certain metabolic disorders. The gene discussed is SOCS3; the disease is metabolic disease.